Izraelis - hebrajų - Ministry of Health

abic marketing ltd, israel - ibuprofen - תרחיף - ibuprofen 100 mg / 5 ml - ibuprofen

Izraelis - hebrajų - Ministry of Health

abic marketing ltd, israel - ibuprofen - תרחיף - ibuprofen 20 mg/ml - ibuprofen

Izraelis - hebrajų - Ministry of Health

abic marketing ltd, israel - ibuprofen - תרחיף - ibuprofen 100 mg / 5 ml - ibuprofen

Izraelis - hebrajų - Ministry of Health

mbi pharma ltd., israel - chenodeoxycholic acid - קפסולה קשיחה - chenodeoxycholic acid 250 mg - chenodeoxycholic acid

Izraelis - hebrajų - Ministry of Health

a.l. medi-market ltd. - rocuronium bromide - תמיסה להזרקה\אינפוזיה - rocuronium bromide 10 mg / 1 ml - rocuronium bromide

Izraelis - hebrajų - Ministry of Health

medison pharma ltd - cx-024414 mrna - cx-024414 mrna 1.26 mg/vial - covid-19 vaccines

Izraelis - hebrajų - Ministry of Health

taro international ltd, israel - sildenafil as citrate - תרחיף - sildenafil as citrate 25 mg / 1 ml - sildenafil

Izraelis - hebrajų - Ministry of Health

novartis israel ltd - epoetin alfa - תמיסה להזרקה - epoetin alfa 1000 iu / 0.5 ml - erythropoietin - erythropoietin - treatment of symptomatic anaemia associated with chronic renal failure (crf) in adult and paediatric patients:- treatment of anaemia associated with chronic renal failure in paediatric and adult patients on haemodialysis and adult patients on peritoneal dialysis.- treatment of severe anaemia of renal origin accompanied by clinical symptoms in adult patients with renal insufficiency not yet undergoing dialysis. treatment of anaemia and reduction of transfusion requirements in adult patients receiving chemotherapy for solid tumours, malignant lymphoma or multiple myeloma, and at risk of transfusion as assessed by the patient's general status (e.g. cardiovascular status, pre existing anaemia at the start of chemotherapy). binocrit can be used to increase the yield of autologous blood from patients in a predonation programme. its use in this indication must be balanced against the reported risk of thromboembolic events. treatment should only be given to non-iron deficient patients with moderate anaemia (haemoglob

Izraelis - hebrajų - Ministry of Health

novartis israel ltd - epoetin alfa - תמיסה להזרקה - epoetin alfa 2000 iu / 1 ml - erythropoietin - erythropoietin - treatment of symptomatic anaemia associated with chronic renal failure (crf) in adult and paediatric patients:- treatment of anaemia associated with chronic renal failure in paediatric and adult patients on haemodialysis and adult patients on peritoneal dialysis.- treatment of severe anaemia of renal origin accompanied by clinical symptoms in adult patients with renal insufficiency not yet undergoing dialysis. treatment of anaemia and reduction of transfusion requirements in adult patients receiving chemotherapy for solid tumours, malignant lymphoma or multiple myeloma, and at risk of transfusion as assessed by the patient's general status (e.g. cardiovascular status, pre existing anaemia at the start of chemotherapy). binocrit can be used to increase the yield of autologous blood from patients in a predonation programme. its use in this indication must be balanced against the reported risk of thromboembolic events. treatment should only be given to non-iron deficient patients with moderate anaemia (haemoglob

Izraelis - hebrajų - Ministry of Health

novartis israel ltd - epoetin alfa - תמיסה להזרקה - epoetin alfa 30000 iu / 0.75 ml - erythropoietin - erythropoietin - treatment of symptomatic anaemia associated with chronic renal failure (crf) in adult and paediatric patients:- treatment of anaemia associated with chronic renal failure in paediatric and adult patients on haemodialysis and adult patients on peritoneal dialysis.- treatment of severe anaemia of renal origin accompanied by clinical symptoms in adult patients with renal insufficiency not yet undergoing dialysis. treatment of anaemia and reduction of transfusion requirements in adult patients receiving chemotherapy for solid tumours, malignant lymphoma or multiple myeloma, and at risk of transfusion as assessed by the patient's general status (e.g. cardiovascular status, pre existing anaemia at the start of chemotherapy). binocrit can be used to increase the yield of autologous blood from patients in a predonation programme. its use in this indication must be balanced against the reported risk of thromboembolic events. treatment should only be given to non-iron deficient patients with moderate anaemia (haemoglob